Article info

Download PDFPDF

Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study

Authors

  1. Correspondence to Dr Thomas Williams, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK; thomas.e.williams{at}ucl.ac.uk
View Full Text

Citation

Williams T, Mishra R, Bharkhada B, et al
Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study

Publication history

  • Received October 28, 2021
  • Accepted February 23, 2022
  • First published March 10, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.